Market Movers (8-K)
OID
BioStem Technologies announced strong sequential revenue growth of 29% to $7.9 million for Q2 2026, raised full-year guidance, and successfully uplisted to the Nasdaq Capital Market.
Capital raise
Quarterly Earnings (10-Q)
OID
BioStem Technologies' Q2 2026 Form 10-Q reveals a significant revenue decrease and increased operating costs, leading to a substantial net loss, though offset by a strategic acquisition and ongoing financing efforts.
Delay expected
Capital raise
Worse than expected
New Public Companies (S-1)
OID
BioStem Technologies files an S-1/A amendment detailing a significant revenue decrease in Q1 2026 compared to the prior year, alongside a net loss, while also outlining strategic acquisitions and future growth plans.
Capital raise
Worse than expected
OID
BioStem Technologies, Inc. has filed an S-1 registration statement to allow a selling stockholder to resell up to 3,571,429 shares of common stock.
Capital raise
Worse than expected